Board Meeting8 Aug 2026, 02:01 pm
Advanced Enzyme Technologies Approves Buyback and Subsidiary Acquisition
AI Summary
Advanced Enzyme Technologies Ltd announced board approval for a share buyback of up to ₹69.7 crore at a maximum price of ₹500 per share, representing 1.24% of its equity. The company also approved acquiring the remaining 4.28% stake in its subsidiary, JC Biotech Private Limited, to make it wholly owned. Additionally, an infusion of up to ₹2 crore was approved for another subsidiary, Advanced Nutrazyme Private Limited. The board also reviewed the un-audited financial results for Q1 FY27.
Key Highlights
- Board approves share buyback of up to ₹69.7 crore.
- Acquires remaining 4.28% stake in JC Biotech, making it wholly owned.
- Approves ₹2 crore fund infusion into Advanced Nutrazyme.
- Reviewed Q1 FY27 un-audited financial results.
Price Impact
More from ADVENZYMES